By Corespondent

Kenya said that the children’s killer cough syrup that is manufactured by Maiden Pharmaceuticals in Haryana, India is not registered in the country.

Dr. Fred Siyoi, the chief executive officer of Pharmacy and Poisons Board said that the syrup that has killed children in Gambia is not available in the Kenyan market.

“There is no cause for alarm as the cough syrups and promethazine products in the Kenyan market meet the market authorization requirements on quality, safety, and efficacy,” Dr. Siyoi said in a statement in Nairobi.

Dr. Siyoi revealed that Kenya has received a medical product pediatric medicines alert from the World Health Organization (WHO) on substandard medical products that is circulating in the Gambia Republic.

The WHO issued the alert over four cough syrups and warned that they could be linked to the deaths of 66 children in Gambia.

He noted that WHO alert is specific to medical products manufactured by Maiden Pharmaceuticals in India, and not any other manufacturing sites.

According to WHO the laboratory analysis of the four products namely; Promethazine Oral Solution (Manufactured by Maiden Pharmaceuticals, India), Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup, found that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants.

The WHO said that the syrups have been potentially linked with acute kidney injuries and 66 deaths among children.

The official however urged Kenyans to be vigilant at all times and report any suspected poor-quality medicines or adverse drug reactions to the nearest healthcare facility.